Urgent Development on PFAS Information Request from CHPSD
Advocacy & Action
Order to apply the SNAc provisions of CEPA to Mitotane CASRN 53-19-0
Proposed Amendments Related to Agile Regulations for Licensing Drugs
Health Canada’s Drug and Medical Device Highlights Report
Publication of Single Ingredient High Dose Vitamin D Monograph
Important Changes at the Consumer & Hazardous Products Safety Directorate
Update on Hydrocarbons INCI Name Change – Cosmetic Notification Form
COVID-19 SL Transition process and New Web-Based SLA Form
Blue Box Trade Associations Working Group Meeting Materials
New Webinar: “GFL Introduces RRA”
